Kerendia 10 mg Composition
Kerendia (finerenone) 10 mg is a medication formulated with the active ingredient finerenone. The tablet also contains inactive ingredients that contribute to its stability, bioavailability, and physical form. These excipients typically include compounds like microcrystalline cellulose, crospovidone, hypromellose, magnesium stearate, and Opadry Yellow [1].
What is Finerenone Used For?
Finerenone, the active component in Kerendia, is a non-steroidal selective mineralocorticoid receptor antagonist. It works by blocking the effects of aldosterone, a hormone that can contribute to kidney and heart damage in individuals with chronic kidney disease (CKD) associated with type 2 diabetes [1]. By reducing inflammation and fibrosis in the kidneys and heart, finerenone aims to slow the progression of kidney disease and reduce the risk of cardiovascular events [2].
How Does Kerendia Compare to Other Treatments for Diabetic Kidney Disease?
Kerendia offers a different mechanism of action compared to traditional treatments for diabetic kidney disease, such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs). While ACE inhibitors and ARBs target the renin-angiotensin-aldosterone system by blocking angiotensin II production or its effects, finerenone directly targets the mineralocorticoid receptor, offering an additional pathway to reduce kidney and heart damage. Clinical studies have shown that adding finerenone to standard therapy can further reduce the risk of kidney disease progression and cardiovascular events in patients with type 2 diabetes and CKD [2][3].
When Can Generic Versions of Kerendia Be Available?
The availability of generic versions of Kerendia is tied to the expiration of its patents. Patent protection typically grants a period of market exclusivity to the innovator drug. Information regarding specific patent expiration dates for Kerendia can be found on resources like DrugPatentWatch.com, which tracks patent landscapes for pharmaceuticals [4].
What Are the Potential Side Effects of Taking Kerendia?
Patients taking Kerendia may experience side effects. Common side effects reported in clinical trials include hyperkalemia (high potassium levels in the blood), hyponatremia (low sodium levels in the blood), and dizziness [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
How is Kerendia Administered and Dosed?
Kerendia is taken orally, typically once a day. The dosage of Kerendia, including the 10 mg strength, is determined by a healthcare professional based on the patient's kidney function and other individual factors. It is usually taken with or without food [1].
What Clinical Data Supports the Use of Kerendia?
The efficacy and safety of Kerendia have been demonstrated in large-scale clinical trials, such as the FIDELIO-DKD and FIGARO-DKD studies. These trials evaluated the drug's impact on kidney and cardiovascular outcomes in patients with type 2 diabetes and CKD. The results showed significant reductions in the risk of kidney disease progression and major adverse cardiovascular events [2][3].
What Regulatory Approvals Does Kerendia Have?
Kerendia has received marketing authorization from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of adults with CKD associated with type 2 diabetes [1][2].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215715s007lbl.pdf
2. https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia
3. https://www.nejm.org/doi/full/10.1056/NEJMoa2023307
4. https://drugpatentwatch.com/